- LYTENAVA is the only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S., and management is preparing commercial, reimbursement, supply and medical-affairs capabilities for a launch later this year.
- Oncobiologics targets $50 million to $75 million of first-year post-launch revenue and more than $500 million in peak annual U.S. sales by 2030, with wholesale acquisition cost below $500 per vial.
- The company reported a $10.9 million adjusted quarterly net loss and $11.2 million of cash as of June 30; the subsequent offering is expected to generate approximately $51.1 million in net proceeds.
- The launch plan includes about 30 customer-facing commercial hires and 20 field reimbursement personnel, with a permanent J-code anticipated in April 2027.
Quotes
“transformational achievement”
“just under a $300 million”